Next Article in Journal
Whole Genome Sequencing for Studying Bacillus anthracis from an Outbreak in the Abruzzo Region of Italy
Previous Article in Journal
The Use of Antimalarial Drugs against Viral Infection
Article

When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii

Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, School of Medicine. Institut d’Investigacions biomèdiques de Bellvitge (IDIBELL), University of Barcelona, 08907 L’Hospitalet, Barcelona, Spain
*
Author to whom correspondence should be addressed.
Microorganisms 2020, 8(1), 86; https://doi.org/10.3390/microorganisms8010086
Received: 6 December 2019 / Revised: 5 January 2020 / Accepted: 5 January 2020 / Published: 8 January 2020
(This article belongs to the Section Antimicrobial Agents and Resistance)
The synergistic action of colistin, with two antibiotics active in Gram-positive bacteria but unable to kill gram negatives (linezolid and rifampicin), was investigated, since triple combinations are emerging as a tool to overtake multidrug resistance. Checkerboard determinations demonstrated that, when combined with colistin, the combination of linezolid and rifampicin turns active in multidrug-resistant Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Thus, the presence of sublethal concentrations of colistin resulted in a strongly synergistic interaction between these two drugs. Moreover, the minimum inhibitory concentrations of linezolid–rifampicin combinations in the presence of colistin were lower than the maximal concentrations of these antimicrobials ain blood. These findings suggest the use of this triple combination as an effective treatment of multidrug-resistant (MDR) bacterial infections. View Full-Text
Keywords: antibiotic combinations; synergism; multidrug-resistant (MDR) bacteria antibiotic combinations; synergism; multidrug-resistant (MDR) bacteria
MDPI and ACS Style

Armengol, E.; Asunción, T.; Viñas, M.; Sierra, J.M. When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Microorganisms 2020, 8, 86. https://doi.org/10.3390/microorganisms8010086

AMA Style

Armengol E, Asunción T, Viñas M, Sierra JM. When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Microorganisms. 2020; 8(1):86. https://doi.org/10.3390/microorganisms8010086

Chicago/Turabian Style

Armengol, Eva, Teresa Asunción, Miguel Viñas, and Josep M. Sierra. 2020. "When Combined with Colistin, an Otherwise Ineffective Rifampicin–Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii" Microorganisms 8, no. 1: 86. https://doi.org/10.3390/microorganisms8010086

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop